![african buffalo - needs credit: Haplochromis [CC BY-SA 3.0 (httpscreativecommons.orglicensesby-sa3.0)]](https://www.pirbright.ac.uk/files/styles/3_by_2_400/public/quick_media/NS19022_African-buffalo-%28Syncerus_caffer%29-Wiki-commons---Credit---Haplochromis-%5BCC-BY-SA-3.0-%28httpscreativecommons.jpg?itok=v1rlPop-×tamp=1558627621 "african buffalo")
Scientists at The Pirbright Institute have shown that African buffalo persistently infected with foot-and-mouth disease (FMD) are unlikely to be the source of new outbreaks in other buffalo and cattle.
Researchers at The Pirbright Institute will partner with the Belgian biotechnology company ViroVet to develop the first antiviral drugs that act against African swine fever (ASF). In the absence of a vaccine, antiviral drugs could provide an alternative control method which would help limit clinical signs in pigs and lower virus replication. This could reduce the spread of disease and help to contain outbreaks, ultimately reducing the number of pigs lost to this deadly viral infection.
Two scientists from The Pirbright Institute attended the BBSRC Innovator of the Year Awards on 15 May 2019 as shortlisted finalists. Dr Andrew Broadbent and Dr Amin Asfor pitched their research against ten other scientists and groups across four categories: Commercial Impact, Social Impact, International Impact and Early Career Impact.
® The Pirbright Institute 2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.
